ClinicalTrials.Veeva

Menu

Remote Symptom Review in Patients With Implantable Diagnostic Holter (BIOMONI-DIG)

A

Andres Iñiguez Romo

Status

Enrolling

Conditions

Bradycardia
Arrythmia
Syncope
Atrial Fibrillation

Treatments

Other: APP

Study type

Interventional

Funder types

Other

Identifiers

Details and patient eligibility

About

To study the clinical and organizational benefit of implementing a methodology for monitoring patients receiving an implantable diagnostic BIOMONITOR III holter and successive models, consisting of remote review of alerts sent by the device via the HOME MONITORING remote monitoring platform and the transmission of relevant patient symptoms through the use of a specific application installable on the patient's phone. The efficiency of this methodology will be compared with a control group consisting of monitoring through the usual clinical practice of the hospital.

Full description

Population of patients: Patients over 18 years old who require the implantation of an implantable diagnostic holter due to indications of syncope or atrial fibrillation, and who are willing to use an application installed on their phone to telematically send clinical symptoms that may occur during the active study period.

Design: Clinical, randomized, prospective, single-center study.

Investigational Device: BIOMONITOR III implantable cardiac holter and successive models with HOMEMONITORING remote monitoring system for constant monitoring of patient's cardiac signals. Installation of the Patient APP on the patient's phone for symptom transmission.

Overall Objective: To study the clinical and organizational benefit of implementing a methodology for monitoring patients receiving an implantable diagnostic BIOMONITOR III holter and successive models, consisting of remote review of alerts sent by the device via the HOME MONITORING remote monitoring platform and the transmission of relevant patient symptoms through the use of a specific application installable on the patient's phone. The efficiency of this methodology will be compared with a control group consisting of monitoring through the usual clinical practice of the hospital.

Enrollment

60 estimated patients

Sex

All

Ages

18 to 80 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Patients indicated for implantation of a subcutaneous implantable holter due to syncope or cryptogenic stroke (atrial fibrillation detection)
  • Patients over 18 years old.
  • Patients who consent to the installation of a patient application for telematic submission of patient-related symptoms.
  • Patients capable of using the patient application.

Exclusion criteria

  • Patients over 80 years of age or, failing that, not able to use an application to send their symptoms.
  • Life expectancy of less than 12 months for any reason.

Trial design

Primary purpose

Diagnostic

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

60 participants in 2 patient groups

Homemonitoring + APP
Experimental group
Description:
The patients receive the usual standard treatment with remote holter monitoring along with an app for the notification of adverse events.
Treatment:
Other: APP
Homemonitoring
No Intervention group
Description:
The patients receive the usual standard treatment with remote holter monitoring

Trial contacts and locations

1

Loading...

Central trial contact

Andrés Iñiguez Romo, MD, PhD; Elvis Teijeira Fernández, MD, PhD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems